A Phase I/II Study of the Safety and Feasibility of REVM10 or REVM10/ANTISENSE POL 1 Transduced Hematopoietic Stem Cells (HSC) in HIV-1 Related Non-Hodgkin's Lymphoma Patients Already Being Treated With High Dose Chemotherapy and Peripheral Blood Stem Cell Support

Inclusion Criteria

DISEASE CHARACTERISTICS: HIV-1 infection documented by ELISA and Western blot
Histologically proven non-Hodgkin's lymphoma showing at least partial response to standard
chemotherapy regimen Poor prognosis in first chemotherapy induced remission Increased LDH
AND/OR Stage III or IV AND/OR Reduced performance status (ECOG 2 or worse) OR Response but
no complete remission following four courses of standard chemotherapy OR Responding
relapse after primary therapy No primary CNS lymphoma No uncontrolled meningeal lymphoma
at mobilization

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: See Disease Characteristics
Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1500/mm3
Platelet count at least 100,000/mm3 CD4 count at least 100/mm3 Hepatic: Bilirubin less
than 2 mg/dL (unless taking indinavir) SGOT and SGPT less than 2 times normal No hepatitis
Renal: Creatinine less than 2.0 mg/dL Pulmonary: DLCO greater than 60% Other: Not pregnant
or nursing Fertile patients must use effective contraception No active Mycobacterium
avium-intracellulare infection or CMV disease No cerebral toxoplasmosis or cryptococcal
meningitis At least 6 months since prior alcohol or substance abuse At least 1 year since
CNS disease or seizures No other medical condition that would preclude study

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
Characteristics No concurrent chemotherapy for Kaposi's sarcoma Endocrine therapy: Not
specified Radiotherapy: Not specified Surgery: Not specified Other: At least 30 days since
prior treatment for serious opportunistic infections